Attached files

file filename
8-K - FORM 8-K - MERGE HEALTHCARE INCd8k.htm
EX-99.3 - NEWS RELEASE - MERGE HEALTHCARE INCdex993.htm
EX-99.1 - TRANSCRIPTS - MERGE HEALTHCARE INCdex991.htm

Exhibit 99.2

 

LOGO

  

News Release

 

FOR IMMEDIATE RELEASE

Press Contact:

Brenda Stewart

Director of Marketing Communications

312 540 6622

brenda.stewart@merge.com

Merge Announces Record Pro Forma Sales of $57M in Second Quarter

GAAP revenue up 92% and adjusted EBITDA up 155% over Q2 2010

Chicago, IL, August, 3, 2011 – Merge Healthcare (NASDAQ: MRGE), a leading provider of enterprise imaging and interoperability solutions, today announced its financial results for the second quarter of 2011.

 

   

Revenue grew to $55.6 million ($57.0 million on a pro forma basis) in the quarter, compared to $29 million ($41.5 million on a pro forma basis) in the second quarter of 2010 - an increase of 92%.

 

   

Adjusted EBITDA was $17.1 million, representing 30% of revenue in the quarter compared to $6.7 million and 23% in the second quarter of 2010 - an increase of 155%.

 

   

Executed 12 new iConnect agreements extending Merge Healthcare’s leadership position in image interoperability market.

 

   

Announced over 30 signed contracts for the Merge Meaningful Use platform within its Orthopaedics and Radiology client base.

Quarter Results:

Results compared to the same quarter in the prior year on a GAAP basis are as follows (in millions, except per share data):

 

     Q2 2011     Q2 2010  

Net sales

   $ 55.6      $ 29.0   

Operating income (loss)

     8.1        (10.6

Net loss available to common shareholders

     (3.3     (30.9

Net loss per diluted share

   ($ 0.04   ($ 0.39

Cash balance at period end

   $ 45.2      $ 37.9   

Cash from core business operations*

     6.6        9.4   

 

* See table at the back of this earnings release.

 

1


Pro forma results and other, non-GAAP measures compared to the same quarter in the prior year are as follows (in millions, except percentages and per share data):

 

     Q2 2011     Q2 2010  

Pro forma results

    

Net sales

   $ 57.0      $ 41.5   

Adjusted net income

     5.0        (4.1

Adjusted EBITDA

     17.1        7.8   

Adjusted net income per diluted share

   $ 0.06      ($ 0.05

Adjusted EBITDA per diluted share

   $ 0.20      $ 0.09   

Non-GAAP and other measures

    

Recurring revenue as % of net sales

     ~62.5     ~65.0

Non-recurring backlog at period end

   $ 40.1      $ 46.0   

Days sales outstanding

     93        94   

Reconciliation of GAAP net income to adjusted net income and adjusted EBITDA is included after the financial information, below.

Explanation of Non-GAAP Financial Measures

Merge Healthcare reports its financial results in accordance with generally accepted accounting principles, or GAAP. This press release includes certain non-GAAP financial measures to supplement its GAAP information. Non-GAAP measures are not an alternative to GAAP and may be different from non-GAAP measures used by other companies. A quantitative reconciliation of GAAP net income available to common shareholders to adjusted net income and adjusted EBITDA is included after the financial information included in this press release.

Management believes that the presentation of non-GAAP results, when shown in conjunction with corresponding GAAP measures, provides useful information to it and investors regarding financial and business trends related to results of operations, because certain charges, costs and expenses reflect events that are not essential to recurring business operations. In addition, management believes these non-GAAP measures provide investors useful information regarding the underlying performance of the post-acquisition business operations when compared to the pre-acquisition results of Merge and any significant acquired company. Purchase accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that are provided and discussed herein. Further, management believes that these non-GAAP measures improve its and investors’ ability to compare Merge’s financial performance with other companies in the technology industry. Management also uses financial statements that exclude these charges, costs and expenses for its internal budgets. While GAAP results are more complete, these supplemental metrics are offered since, with reconciliations to GAAP, they may provide greater insight into our financial results. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP.

Additional information regarding the non-GAAP financial measures presented is as follows:

 

2


   

Pro forma revenue consists of GAAP revenue as reported, adjusted to reflect the acquisition of AMICAS as if it had occurred at the beginning of the respective periods presented and to add back the acquisition related sales adjustment (for all significant acquisitions) booked for GAAP purposes.

 

   

Recurring revenue is generated from agreements that generally contain a stated annual amount and which we have a high likelihood of renewing each year. More specifically, this includes revenue generated from our DICOM toolkit and eFilm Workstation® product lines, long-term contracts associated with our Sales as a Service (SaaS) related offerings, and EDI and maintenance contracts across the entire business.

 

   

Non-recurring revenue backlog represents revenue that we anticipate recognizing in future periods from signed customer contracts as of the end of the period presented. Non-recurring revenue is comprised of all other sources of revenue not included as recurring revenue, primarily from perpetual software licenses, hardware and professional services (including installation, training and consultative engineering services).

 

   

Adjusted net income consists of GAAP net income available to common stockholders, adjusted to reflect the acquisition of AMICAS as if it had occurred at the beginning of the respective period presented and, to the extent such items occurred in the periods presented, excludes (a) one-time preferred stock deemed dividend at issuance date, (b) acquisition-related costs, (c) restructuring and other costs, (d) stock-based compensation expense, (e) acquisition-related amortization, and (f) acquisition-related cost of sales adjustments and adds back (g) the acquisition-related sales adjustments.

 

   

Adjusted EBITDA adjusts GAAP net income available to common stockholders for the items considered in adjusted net income as well as (a) remaining depreciation and amortization, (b) net interest expense, (c) non-cash preferred stock dividends and (d) income tax expense (benefit).

 

   

Cash from core business operations reconciles the cash generated from such operations to the change in GAAP cash balance for the period by reflecting payments of liabilities associated with our acquisitions, payments of acquisition related fees, interest payments and other payments and receipts of cash not generated by the business operations.

Management has excluded certain items from non-GAAP adjusted net income because it believes (i) the amount of certain expenses in any specific period may not directly correlate to the underlying performance of business operations and (ii) the adjustment facilitates comparisons of pre-acquisition results to post-acquisition results. In addition, the following adjustments are described in more detail below:

 

   

Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with significant acquisitions. Management excludes acquisition-related amortization expense from non-GAAP net income because it believes such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets.

 

   

Stock-based compensation expense is a non-cash expense arising from the grant of stock awards to employees and is excluded from non-GAAP net income because management believes such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants to new employees resulting from acquisitions.

 

   

Acquisition related sales and costs of sales adjustments reflect the fair value adjustment to deferred revenues acquired in connection with significant acquisitions. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an

 

3


 

appropriate profit margin to perform services-related software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the date the acquisition of a significant company was completed. Management adds back this deferred revenue adjustment, net of related costs, for non-GAAP revenue and non-GAAP net income because it believes the inclusion of this amount directly correlates to the underlying performance of operations and facilitates comparisons of pre-acquisition to post-acquisition results.

Notice of Conference Call:

Merge will host a conference call on Wednesday, August 3, 2011, at 8:30 am EDT to discuss its financial results for the second quarter 2011. Jeff Surges, CEO, and Justin Dearborn, CFO, will co-chair the call. Investors can listen to the conference call live via telephone by dialing 800.221.2015 (US and Canada) or 706.634.2159 (International), and referencing Conference ID Number 85680351. Alternatively, the call can be accessed over the Internet at Merge Healthcare Web Cast. The conference call will be recorded and the recording may be found via the internet shortly after the call at http://www.merge.com/Company/Investors/Conference-Call-Info.aspx.

Merge Healthcare develops and integrates information technology to create a better electronic healthcare experience. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years. Additional information can be found at www.merge.com.

# # #

Cautionary Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements,” including statements which are related to future, not past, events. Forward-looking statements usually describe expected future business and financial outlook or performance, and often contain words such as “will,” “believes,” “intends,” “anticipates,” “expects,” “plans,” “seeks,” “see” and similar expressions. Forward-looking statements, by their nature, address matters that are, to varying degrees, uncertain and subject to various known and unknown risks. For Merge, particular uncertainties and risks that could cause actual results to differ materially from post-merger forward-looking statements include, among other issues: the successful integration of companies we acquire; achieving certain post-acquisition synergies; the market acceptance of implemented product solutions; market acceptance and performance of Merge’s products and services; the impact of competitive products and pricing; possible delays in the implementation of its managed services offering; the risks and effects of its recent changes in its executive and Board leadership, including the costs and expenses related to severance payments made to departing officers; the risks and effects of its recent securities issues, including the issuance of certain senior secured notes; the past restatement of its financial statements and other actions that may be taken or required as a result of such restatement; its ability to generate sufficient cash from operations to meet future operating, financing and capital requirements, including repayment obligations with respect to its outstanding indebtedness; risks associated with its prior delays in filings with the SEC or its ability to continue to meet the listing requirements of The NASDAQ Global Select Market; the costs, risks and effects of various pending legal proceedings; and other risk factors detailed in its filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Merge does not undertake any obligation to update forward-looking statements or any of risks, uncertainties and other factors.

 

4


MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

     June 30,
2011
     December 31,
2010
 
     (Unaudited)         

Current assets:

     

Cash (including restricted cash)

   $ 45,234       $ 41,029   

Accounts receivable, net

     58,481         53,254   

Inventory

     3,095         3,486   

Prepaid expenses

     3,679         4,191   

Deferred income taxes

     2,545         2,545   

Other current assets

     11,853         9,336   
  

 

 

    

 

 

 

Total current assets

     124,887         113,841   

Property and equipment, net

     5,008         5,772   

Purchased and developed software, net

     24,016         26,619   

Other intangible assets, net

     41,986         48,957   

Goodwill

     171,578         169,533   

Deferred tax assets

     14,566         17,006   

Other

     13,578         14,660   
  

 

 

    

 

 

 

Total assets

   $ 395,619       $ 396,388   
  

 

 

    

 

 

 

Current liabilities:

     

Accounts payable

   $ 16,629       $ 18,370   

Interest payable

     4,935         3,917   

Accrued wages

     6,426         4,304   

Restructuring accrual

     1,027         1,707   

Other accrued liabilities

     7,772         6,875   

Deferred revenue

     42,134         49,876   
  

 

 

    

 

 

 

Total current liabilities

     78,923         85,049   

Notes payable

     249,065         195,077   

Deferred revenue

     5,104         3,809   

Income taxes payable

     5,707         5,683   

Other

     1,464         1,964   
  

 

 

    

 

 

 

Total liabilities

     340,263         291,582   

Total shareholders’ equity

     55,356         104,806   
  

 

 

    

 

 

 

Total liabilities and shareholders’ equity

   $ 395,619      

$

396,388

  

  

 

 

    

 

 

 

 

5


MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2011     2010     2011     2010  

Net sales

        

Software and other

   $ 17,639      $ 6,592        36,310      $ 15,957   

Professional services

     10,515        5,631        18,915      $ 9,377   

Maintenance and EDI

     27,438        16,780        53,039        23,639   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net sales

     55,592        29,003        108,264        48,973   

Cost of sales

        

Software and other

     4,681        1,690        11,258        2,394   

Professional services

     5,016        4,028        10,079        7,025   

Maintenance and EDI

     6,687        5,809        14,651        7,306   

Depreciation, amortization and impairment

     2,347        4,487        4,846        5,705   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of sales

     18,731        16,014        40,834        22,430   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross margin

     36,861        12,989        67,430        26,543   

Operating costs and expenses:

        

Sales and marketing

     7,853        4,189        16,546        7,008   

Product research and development

     7,017        5,752        13,769        9,008   

General and administrative

     8,264        5,591        14,854        9,442   

Acquisition-related expenses

     375        2,421        479        8,359   

Restructuring and other expenses

     —          3,483        (36     3,483   

Depreciation, amortization and impairment

     5,223        2,181        7,873        3,021   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

     28,732        23,617        53,485        40,321   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     8,129        (10,628     13,945        (13,778

Other expense, net

     (7,788     (4,275     (14,348     (4,229
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     341        (14,903     (403     (18,007

Income tax expense

     2,026        58        2,871        106   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

     (1,685     (14,961     (3,274     (18,113

Less: preferred stock dividends

     1,587        15,944        3,153        15,944   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss available to common shareholders

   $ (3,272   $ (30,905   $ (6,427   $ (34,057
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share - basic

   $ (0.04   $ (0.39   $ (0.08   $ (0.44
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average number of common shares outstanding - basic

     84,345,025        80,092,926        84,277,343        77,461,669   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share - diluted

   $ (0.04   $ (0.39   $ (0.08   $ (0.44
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average number of common shares outstanding - diluted

     84,345,025        80,092,926        84,277,343        77,461,669   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

6


MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

           Six Months Ended
June 30,
 
           2011     2010  

Cash flows from operating activities:

      

Net loss

     $ (3,274   $ (18,113

Adjustments to reconcile net loss to net cash provided by operating activities:

      

Depreciation, amortization and impairment

       12,719        8,726   

Share-based compensation

       2,120        816   

Change in contingent consideration for acquisitions

       128        342   

Amortization of notes payable issuance costs & discount

       1,156        452   

Provision for doubtful accounts receivable and sales returns, net of recoveries

       782        (277

Deferred income taxes

       2,440        —     

Gain on sale of equity investment

       (405     —     

Net change in assets and liabilities (net of effects of acquisitions)

       (13,063     9,921   
    

 

 

   

 

 

 

Net cash provided by operating activities

       2,603        1,867   

Cash flows from investing activities:

      

Cash paid for acquisitions, net of cash acquired

       (600     (210,226

Purchases of property, equipment and leasehold improvements

       (1,277     (745

Change in restricted cash

       880        42   

Distribution from equity investment

       405        76   
    

 

 

   

 

 

 

Net cash used in investing activities

       (592     (210,853

Cash flows from financing activities:

      

Proceeds from issuance of notes

       53,560        194,532   

Proceeds from issuance of stock

       —          41,750   

Note and stock issuance costs paid

       (1,528     (8,946

Proceeds from exercise of stock options and employee stock purchase plan

       206        57   

Principal payments on capital leases

       (41     (48

Redemption and retirement of preferred stock

       (41,750     —     

Preferred stock dividends

       (7,328     —     
    

 

 

   

 

 

 

Net cash provided by financing activities

       3,119        227,345   
    

 

 

   

 

 

 

Effect of exchange rate changes on cash

       (45     —     
    

 

 

   

 

 

 

Net increase in cash

       5,085        18,359   

Cash and cash equivalents, beginning of period (net of restricted cash)

     (1     39,382        19,062   
    

 

 

   

 

 

 

Cash and cash equivalents, end of period (net of restricted cash)

     (2   $ 44,467      $ 37,421   
    

 

 

   

 

 

 

 

(1) Restricted cash of $1,647 and $559 as of December 31, 2010 and 2009, respectively.
(2) Restricted cash of $767 and $517 as of June 30, 2011 and 2010, respectively.

 

7


MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES

RECONCILIATION OF NET LOSS AVAILABLE TO COMMON SHAREHOLDERS TO ADJUSTED EBITDA

(in thousands)

(unaudited)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2011     2010     2011     2010  

Net loss available to common shareholders

   $ (3,272   $ (30,905   $ (6,427   $ (34,057

One-time preferred stock deemed dividend at issuance date

     —          14,900        —          14,900   

Acquisition related costs

     375        2,421        479        8,359   

Restructuring and other

     —          3,483        (36     3,483   

Stock-based compensation expense

     1,058        462        2,120        816   

Amortization of significant acquisition intangibles

     5,604        3,378        8,692        3,879   

Acquisition-related sales adjustments

     1,411        5,111        2,748        5,439   

Acquisition-related cost of sales adjustments

     (216     (892     (288     (892
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted net income (loss)

   $ 4,960      $ (2,042   $ 7,288      $ 1,927   

Depreciation, amortization and impairment

     1,966        3,290        4,027        4,847   

Net interest expense

     6,579        4,308        12,933        4,298   

Preferred stock dividends

     1,587        1,044        3,153        1,044   

Income tax expense

     2,026        58        2,871        106   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $ 17,118      $ 6,658      $ 30,272      $ 12,222   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted net income per share - diluted

   $ 0.06      $ (0.03   $ 0.08      $ 0.02   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA per share - diluted

   $ 0.20      $ 0.08      $ 0.35      $ 0.15   
  

 

 

   

 

 

   

 

 

   

 

 

 

Fully diluted shares (if net income)

     87,562,218        81,767,889        87,080,877        79,159,298   
  

 

 

   

 

 

   

 

 

   

 

 

 
     Pro Forma Three Months
Ended June 30,
    Pro Forma Six Months
Ended June 30,
 
     2011     2010     2011     2010  

Net loss available to common shareholders

   $ (2,077   $ (27,176   $ (3,967   $ (28,306

One-time preferred stock deemed dividend at issuance date

     —          14,900        —          14,900   

Acquisition related costs

     375        6        479        261   

Restructuring and other

     —          3,483        (36     3,483   

Stock-based compensation expense

     1,058        462        2,120        816   

Amortization of significant acquisition intangibles

     5,604        4,181        8,692        6,613   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted net income (loss)

   $ 4,960      $ (4,144   $ 7,288      $ (2,233

Depreciation, amortization and impairment

     1,966        3,790        4,027        6,335   

Net interest expense

     6,579        6,492        12,933        13,050   

Non-cash preferred stock dividend

     1,587        1,566        3,153        3,132   

Income tax expense

     2,026        58        2,871        152   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $ 17,118      $ 7,762      $ 30,272      $ 20,436   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted net income (loss) per share - diluted

   $ 0.06      $ (0.05   $ 0.08      $ (0.03
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA per share - diluted

   $ 0.20      $ 0.09      $ 0.35      $ 0.24   
  

 

 

   

 

 

   

 

 

   

 

 

 

Fully diluted shares (if net income)

     87,562,218        84,080,197        87,080,877        84,058,580   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

8


MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES

CASH FROM CORE BUSINESS OPERATIONS

(unaudited)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2011     2010     2011     2010  
     (amounts in millions)  

Cash received from (paid for):

        

Issuance of debt and equity

   $ 53.6      $ 232.0      $ 53.6      $ 236.3   

Debt and equity issuance costs

     (2.5     (7.3     (2.5     (8.9

Redemption of preferred stock

     (40.8     —          (40.8     —     

Payment of preferred stock dividends

     (7.1     —          (7.1     —     

Interest paid

     (10.9     —          (10.9     —     

Acquisitions

     (0.6     (208.8     (0.6     (210.2

Restructuring initiatives

     (0.3     (1.0     (0.9     (1.4

Acquisition related costs

     —          (2.2     (0.4     (7.1

Property and equipment purchases

     (0.9     (0.2     (1.2     (0.8

Settlements with former officers

     —          —          (0.9     —     

Other non-operating cash flows

     0.4        0.2        0.4        0.2   

Core business operations

     6.6        9.4        15.5        10.2   
  

 

 

   

 

 

   

 

 

   

 

 

 

Increase (decrease) in cash

   $ (2.5   $ 22.1      $ 4.2      $ 18.3   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

9